 After submitting a written response to the FDAs request for additional information on Meridian Bioscience Incs NASDAQ: VIVO Revogene SARS-CoV-2 test on February 16 and further discussions with the FDA, the company decided to withdraw its Emergency Use Authorization EUA application. The company plans to conduct a new clinical validation study and a Limit-of-Detection bridging study, with potential re-submission of a EUA application during Q3 of 2021. 